Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02531087

Urinary Biomarkers of OI Pathobiology

Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss, dental problems, pain and difficulty getting around. Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Shriners Hospital for Children, Montreal, Quebec, Canada

Loading trial locations.

About this study

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. OI can range from very severe to very mild. Individuals with the most severe type of OI may die at birth. People with severe OI who survive may have bowed arms and legs, very short stature and be unable to walk. People with the mildest form of OI may only break bones occasionally and have normal height and lifespan. Breaks can occur in any bone, but are most common in the arms and legs. People with OI also often have problems with the spine. The spine problems include compression fractures and scoliosis (a curvature of the spine). DI is characterized by grey or brown teeth that may chip and wear down and break easily. In addition to weak teeth, the teeth in the upper jaw may not match up with the teeth in the lower jaw.

Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. In the past decade, it was discovered that in about 5% of people with OI it is in another gene. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • To be able to participate, you must:

Be enrolled in The Longitudinal Study of OI (NTC #02432625) and have one of the following genetic mutations:

  • glycine substitution mutations in COL1A1 or COL1A2
  • haploinsufficient mutation in COL1A1 or COL1A2
  • mutations in CRTAP, PPIB, or LEPRE1
  • mutations in FKBP10 or SERPINH1
  • mutations in (SERPINF1, WNT1, or IFITM5)
  • dominant negative glycine substitutions and haploinsufficient mutations in COL1A1, and COL1A2

If you are serving as a control, you must not be related to an individual with OI.

Exclusion criteria

  • You cannot participate if:
  • You are unable to comply with the sample collection schedule.
  • You are related to one of the OI subjects and would like to serve as a control subject.
  • You have vertebral instrumentation or spinal deformities where we cannot assess lumbar spine aBMD.
  • You have a history of recent fracture (< 3 months).
  • You have serum creatinine above 1x upper limits of normal.
  • You have abnormal kidney function.
  • You are using Minoxidil.
  • You are unable to provide a urine sample readily.

Treatment and study plan

Primary outcomes

  1. HP/LP Ratio

    Time frame: 5 Years

    The endpoint will be to compare the HP/LP ratio in OI patients with collagen overmodification (dominant negative mutations in COL1A1, COL1A2, and biallelic mutations in CRTAP, LEPRE1, PPIB) to those without overmodification (FKBP10, SERPINH1, IFITM5, SERPINF1, WNT1, and haploinsufficient mutations in COL1A1 and COL1A2).

Secondary outcomes

  1. HP/LP ratio

    Time frame: 5 Years

    The endpoint would be the HP/LP ratio in those with dominant negative type I collagen mutations vs. those with mutations in P3H complex.

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Collaborators

  • Shriners Hospitals for Children
  • University of Nebraska
  • University of Washington

Registry information

Official study title

Cross-Linked Collagen Peptides as a Urinary Biomarker of OI Pathobiology

Important dates

Study start
2015
Primary completion
2019
Study completion
2026
First posted
Aug 24, 2015
Registry last updated
Dec 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.